1,2-环己二醇,3-亚甲基-6-(1-甲基乙基)-,(1R,2R,6R)-rel- | 82799-45-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 中文名称: 1,2-环己二醇,3-亚甲基-6-(1-甲基乙基)-,(1R,2R,6R)-rel-
• 中文别名: 2,4-二乙基-9H-噻吨-9-酮10,10-二氧化物
• 英文名称: 2,4-Diethyl-9H-thioxanthen-9-one 10,10-dioxide
• 英文别名: 2,4-diethyl-10,10-dioxothioxanthen-9-one
• CAS: 82799-45-9
• 化学式: C₁₇H₁₆O₃S
• 分子量: 300.4
• InChiKey: NKVRNMCFIYCIQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Methods of treating conditions associated with an Edg-7 receptor
  申请人：——

  公开号：US20040167165A1

  公开（公告）日：2004-08-26

  In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject.

  在一个方面，本发明提供了一种调节细胞中Edg-7受体介导的生物活性的方法。将表达Edg-7受体的细胞与能够调节Edg-7受体介导的生物活性的Edg-7受体调节剂接触。在另一个方面，本发明提供了一种调节主体中Edg-7受体介导的生物活性的方法。向主体内给予Edg-7受体调节剂的治疗有效量。
• METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR
  申请人：SRI INTERNATIONAL

  公开号：EP1513522A2

  公开（公告）日：2005-03-16
• [EN] METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR<br/>[FR] PROCEDES POUR TRAITER DES PATHOLOGIES ASSOCIEES A UN RECEPTEUR D'EDG
  申请人：CERETEK LLC

  公开号：WO2003062392A2

  公开（公告）日：2003-07-31

  The present invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor mediated biological activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biological in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject.